Conclusion

Respiratory Medicine

Volumn 97, Issue SUPPL. 2, 2003, Pages

  Bousquet, J ^a   Delacourt, C ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; ANTIASTHMATIC AGENT; BECLOMETASONE;

ADRENAL GLAND; ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG INJURY; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; ARTICLE;

ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; HUMANS; METERED DOSE INHALERS;

EID: 85059049480     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)90077-1     Document Type: Article

References (4)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
2. Terzano C, Allegra L, Barkai L, Cremonesi G. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci 2000; 4: 17-24.
3. Berglund E. Inhalation therapy: Problems and prospects. Eur Respir J 1990; 3: 830.
4. Pedersen S, Frost L, Arufred T. Errors in inhalation technique and efficacy in inhaler use in asthmatic children. Allergy 1986; 41: 118.